[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356058-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356058-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cell-surface-adgrg1-and-cd86-expression-identifies-antitumor-cd4-t-cells-in-human-cancer","Cell surface ADGRG1 and CD86 expression identifies antitumor CD4+ T cells in human cancer","","Adoptive cell transfer of tumor-infiltrating CD4+ T cells can drive durable regression in advanced solid tumors, yet reliable cell-surface protein markers for isolating antitumor CD4+ T cells have remained unclear. This study defines transcriptomic and matching cell-surface protein profiles of antitumor CD4+ tumor-infiltrating lymphocytes in metastatic colorectal cancer using high-dimensional single-cell transcriptomics and proteomics. Across 45 antitumor CD4+ TCR clonotypes, ADGRG1 and CD86 uniquely mark reactive clonotypes with 11-fold and 9-fold enrichment versus bulk CD4+ TIL, enabling isolation of validated tumor-reactive TCRs.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cell-surface-adgrg1-and-cd86-expression-identifies-antitumor-cd4-t-cells-in-human-cancer/356058/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cell-surface-adgrg1-and-cd86-expression-identifies-antitumor-cd4-t-cells-in-human-cancer/356058.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are cell-surface protein markers needed for antitumor CD4+ T cells?","Question",{"text":63,"@type":64},"Transcriptomic signatures can identify antitumor CD4+ T cells, but cell-surface markers are needed to isolate and enrich viable cells for downstream functional study and ACT clinical workflows.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were ADGRG1 and CD86 evaluated in the study?",{"text":68,"@type":64},"The authors performed high-dimensional single-cell transcriptomic and proteomic analysis of antitumor CD4+ TIL within metastatic colorectal tumors to derive transcriptomic and cell-surface protein profiles.",{"name":70,"@type":61,"acceptedAnswer":71},"What enrichment did ADGRG1 and CD86 provide for neoantigen-reactive CD4+ TCR clonotypes?",{"text":72,"@type":64},"In samples containing tumor neoantigen-reactive CD4+ TIL clonotypes, ADGRG1- and CD86-based enrichment of known reactive clonotypes was 11-fold and 9-fold higher than bulk CD4+ TIL, respectively.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356058,1790299548,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","RESEARCH ARTICLE  \nIMMUNOLOGY AND INFLAMMATION  \n OPEN ACCESS  \nCell surface ADGRG1 and CD86 expression identiﬁes antitumor CD4 + T cells in human cancer  \nKyle J. Hitschericha,1, Aaron J. Dinermana,1, Abraham A. Hakima,1, Victoria Dulembaa, Sivasish Sindiria, Billel Gasmia, Alakesh Beraa, Jared J. Gartnera, Todd D. Pricketta, Zhiya Yua, Yong F. Lia, Nivedita M. Ratnama, Alexandra M. Gustafsona , Aarushi Bhasina, Maria R. Parkhursta, Nicholas D. Klemena,  \nMei Li M. Kwonga , James C. Yanga , Paul F. Robbinsa, Stephanie L. Goffa, Steven A. Rosenberga, Sri Krishnaa,2, and Frank J. Lowerya,2 Affiliations are included on p. 11.  \nEdited by Owen N. Witte, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA; received July 30, 2025; accepted June 1, 2026  \nAdoptive cell transfer of tumor inﬁltrating CD4+ T cells or T cells genetically modiﬁed to express antitumor CD4+ T cell receptors (TCRs) has shown clinical eﬃcacyin patients with advanced solid tumors. We previously deﬁned unique transcriptomic states of antitumor, neoantigen-speciﬁc CD8+ and CD4+ tumor inﬁltrating lymphocytes (TIL) in human cancer. However, optimal cell surface protein markers that identify and would enable viable cell isolation and selective enrichment of antitumor CD4+ T cells have yet to be identiﬁed. Here, we deﬁne transcriptomic and corresponding cell surface protein proﬁles of antitumor CD4+ TIL within metastatic colorectal tumors using high dimensional single cell transcriptomic and proteomic analysis. Comprehensive analysis of 45 antitumor CD4+ TCR clonotypes demonstrated uniquely high cell surface protein expression of ADGRG1, CD86, and CD57 . In all samples containing tumor neoantigen-reactive CD4+ TIL clonotypes, ADGRG1-and CD86-based cell surface enrichment of known reactive TCR clonotypes were 11-fold and 9-fold higher than bulk CD4+ TIL, respectively. ADGRG1-and CD86-based cell surface enrichment identiﬁed >60 validated antitumor CD4+ TCR-clonotypes including tumor organoid-reactive TCRs, as well as neoantigen-speciﬁc TCRs targeting private tumor mutations and cancer driver mutations. While both ADGRG1 and CD86 enriched CD4+ TIL displayed an exhausted neoantigen-speciﬁc gene expression signature, CD86 also enriched for cytotoxic CD4+ TIL phenotypes. CD4+ TIL isolated based on ADGRG1 expression and expanded in vitro also demonstrated neoantigen reactivity in two samples. Thus, ADGRG1 and CD86 appear to be eﬀective protein markers for isolating human tumor-speciﬁc CD4+ TCR clonotypes and studying antitumor CD4+ TIL.  \nCD4 | T cell | cancer | neoantigen | ADGRG1  \nAdoptive cell transfer (ACT) of autologous lymphocytes targeting tumor antigens has mediated durable tumor regressions in patients with metastatic solid tumors ( 1–7) . Although the importance of CD8+ T cells in mediating ACT response is well established (8–11), the critical role of CD4+ antitumor T cells in mediating durable antitumor responses following ACT has only recently come to the forefront (3, 7, 9, 12–17) . In one patient with metastatic cholangiocarcinoma, an ACT infusion product composed almost entirely of neoantigen-specific CD4+ T cells resulted in a durable response (3). ACT using peripheral blood lymphocytes (PBL) genetically modified to express tumor reactive TCRs (TCR-T cell therapy) has also shown efficacy in the treatment of patients with advanced stage malignancies (9, 12, 18) . In a recent clinical trial, TCR-T cell therapy based on a human leukocyte antigen (HLA)-class II-restricted TCR specific for the cancer germline antigen MAGE-A3 mediated regression of metastatic melanoma, further demonstrating that ACT of CD4+ T cells can lead to regressions of solid tumors in patients with advanced stage cancer ( 12) .  \nWe and others have previously demonstrated success in defining the unique transcriptomic states of antitumor CD8+ and CD4+ T cells from freshly dissociated human tumor samples (noncultured) (19–23). We recently described a CD4+ T","cbCaiiEq7iJOCts0","https://ap.wps.com/l/cbCaiiEq7iJOCts0","pdf",5473342,12,"English","# Significance\n# Competing interest statement\n# Article submission and copyright","[{\"question\":\"Why are cell-surface protein markers needed for antitumor CD4+ T cells?\",\"answer\":\"Transcriptomic signatures can identify antitumor CD4+ T cells, but cell-surface markers are needed to isolate and enrich viable cells for downstream functional study and ACT clinical workflows.\"},{\"question\":\"How were ADGRG1 and CD86 evaluated in the study?\",\"answer\":\"The authors performed high-dimensional single-cell transcriptomic and proteomic analysis of antitumor CD4+ TIL within metastatic colorectal tumors to derive transcriptomic and cell-surface protein profiles.\"},{\"question\":\"What enrichment did ADGRG1 and CD86 provide for neoantigen-reactive CD4+ TCR clonotypes?\",\"answer\":\"In samples containing tumor neoantigen-reactive CD4+ TIL clonotypes, ADGRG1- and CD86-based enrichment of known reactive clonotypes was 11-fold and 9-fold higher than bulk CD4+ TIL, respectively.\"}]","Cell surface ADGRG1 and CD86 expression identifies antitumor CD4+ T cells in human cancer | PDF",1790123118,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8655572fa556854c4d811cc01c8e1c31.webp",983,1316,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdbc520ecbd386300463a32270b5309c.webp",982,1315,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a20152bcd1e60a81bbaee0983bb8920.webp",981,1313,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7684947b493156a69e49845a628aa973.webp",980,1312]